









Markets
/
Stocks
/
nasdaq-grfs
/

Grifols SA

GRFS

9.740USD

-0.080-0.81%

Close 09/19, 16:00（ET）Quotes delayed by 15 min

6.63BMarket Cap

20.34P/E TTM



Grifols SA

9.740

-0.080-0.81%

Overview Company Financials Analysis

TradingKey Stock Score

Overall Financial Health

Valuation Dimensions

Earnings Forecast

Price Momentum

Institutional Confidence

Risk Assessment

Peer Comparison

TradingKey Stock Score

Currency: USD Updated: 2025-09-19

Key Insights

The company's fundamentals are relatively healthy. Its valuation is considered undervalued,and institutional recognition is very high. Over the past 30 days, multiple analysts have rated the company as a Buy. Despite an average stock market performance, the company shows strong fundamentals and technicals. The stock price is trading sideways between the support and resistance levels, making it suitable for range-bound swing trading.

Score

Industry at a Glance

Industry Ranking

65 / 175

Overall Ranking

203 / 4720

Industry

Pharmaceuticals

Support & Resistance

No Data

Score Analysis

Current score

Previous score

Analyst Rating

Based on 8 analysts

Buy

Current Rating

14.070

Target Price

+43.28%

Upside Space

Data disclaimer: Analyst ratings and target prices are provided by LSEG for informational purposes only and do not constitute investment advice.

Company Highlights

StrengthsRisks

Grifols SA is a Spain-based global specialty pharmaceutical company developing, manufacturing and distributing a broad range of biological medicines based on plasma derived proteins. The Company organizes its business into five divisions: Bioscience, Diagnostic, Hospital, Bio Supplies and Others. Bioscience includes manufacturing activities of plasma derivatives for therapeutic use and the sale and distribution of end products. Its diagnostic focuses on researching, developing, manufacturing and marketing in vitro diagnostics products, such as analytical instruments, reagents and software, among others, for laboratories. Hospital offers technology and services for hospitals, clinics and specialized centers for the manufacture of medicines, as well as physiological saline solution, enteral nutritional fluids and medical devices for interventional therapy. Its bio Supplies provides, mostly, biological products for non-therapeutic use.

High Growth

The company's revenue has grown steadily over the past 3 years, averaging 22.33% year-on-year.

Undervalued

The company’s latest PE is 20.33, at a low 3-year percentile range.

Institutional Selling

The latest institutional holdings are 150.67M shares, decreasing 5.53% quarter-over-quarter.

Held by Brandes Investmen

Star Investor Brandes Investmen holds 28.04M shares of this stock.

Financial Health

Currency: USD Updated: 2025-09-19

The company's current financial score is 8.48, which is higher than the Pharmaceuticals industry's average of 7.84. Its financial status is stable, and its operating efficiency is high. Its latest quarterly revenue reached 2.14B, representing a year-over-year increase of 9.52%, while its net profit experienced a year-over-year increase of 730.43%.

Score

Industry at a Glance

Previous score

8.48

Change



Financials

6.01

Key Metrics

Cash and cash equivalents

Total assets

Total liabilities

Free cash flow

No Data



Quality of Earnings

8.67

Key Metrics

Total revenue

Operating profit

Total assets

SG&A

No Data



Operational Efficiency

10.00

Key Metrics

Cash flow from operating activities

Income after tax

No Data



Growth Potential

10.00

Key Metrics

Cash flow from operating activities

Total revenue

No Data



Shareholder Returns

7.70

Key Metrics

Free cash flow

No Data

Company Valuation

Currency: USD Updated: 2025-09-19

The company’s current valuation score is 1.80, which is lower than the Pharmaceuticals industry's average of 2.06. Its current P/E ratio is 20.50, which is 50.82% below the recent high of 30.92 and -9.17% above the recent low of 22.38.

Score

Industry at a Glance

Previous score

1.80

Change

Valuation Dimensions

P/E

P/B

P/S

P/CF

Industry Ranking 65/175

No Data

Earnings Forecast

Currency: USD Updated: 2025-09-19

The company’s current earnings forecast score is 7.00, which is lower than the Pharmaceuticals industry's average of 7.78. The average price target for Grifols SA is 14.07, with a high of 14.07 and a low of 14.07.

Score

Industry at a Glance

Previous score

7.00

Change

Support & Resistance

No Data

Analyst Rating

Based on 8 analysts

Buy

Current Rating

14.070

Target Price

+43.28%

Upside Space

Strong Buy

Buy

Hold

Sell

Strong Sell

Peer Comparison

179

Total

Median

Average

Company name

Ratings

Analysts

Grifols SA

GRFS

Biogen Inc

BIIB

Amgen Inc

AMGN

Vertex Pharmaceuticals Inc

VRTX

Alnylam Pharmaceuticals Inc

ALNY

Eli Lilly and Co

LLY

...

Financial Forecasting

EPS

Revenue

Net Profit

EBIT

No Data

Data disclaimer: Analyst ratings and target prices are provided by LSEG for informational purposes only and do not constitute investment advice.

Price Momentum

Currency: USD Updated: 2025-09-19

The company’s current price momentum score is 6.80, which is lower than the Pharmaceuticals industry's average of 6.84. Sideways: Currently, the stock price is trading between the resistance level at 10.18 and the support level at 9.52, making it suitable for range-bound swing trading.

Score

Industry at a Glance

Previous score

6.80

Change

-0.21

Support & Resistance

No Data

Indicators



The Indicators feature provides value and direction analysis for various instruments under a selection of technical indicators, together with a technical summary.

This feature includes nine of the commonly used technical indicators: MACD, RSI, KDJ, StochRSI, ATR, CCI, WR, TRIX and MA. You may also adjust the timeframe depending on your needs.

Please note that technical analysis is only part of investment reference, and there is no absolute standard for using numerical values to assess direction. The results are for reference only, and we are not responsible for the accuracy of the indicator calculations and summaries.

Indicators

Sell(3)

Neutral(4)

Buy(0)

Indicators

Value

Direction

MACD(12,26,9)

-0.031

Sell

RSI(14)

44.501

Neutral

STOCH(KDJ)(9,3,3)

25.528

Neutral

ATR(14)

0.249

Low Volatility

CCI(14)

-66.470

Neutral

Williams %R

73.282

Sell

TRIX(12,20)

-0.185

Sell

StochRSI(14)

66.223

Neutral

Moving Average

Sell(4)

Neutral(0)

Buy(2)

Indicators

Value

Direction

MA5

9.754

Sell

MA10

9.853

Sell

MA20

9.864

Sell

MA50

10.130

Sell

MA100

9.227

Buy

MA200

8.326

Buy

Institutional Confidence

Currency: USD Updated: 2025-09-19

The company’s current institutional recognition score is 5.00, which is lower than the Pharmaceuticals industry's average of 6.26. The latest institutional shareholding proportion is 58.35%, representing a quarter-over-quarter decrease of 0.59%. The largest institutional shareholder is Brandes Investmen, holding a total of 28.04M shares, representing 10.86% of shares outstanding, with 36.78% increase in holdings.

Score

Industry at a Glance

Previous score

5.00

Change

Institutional Shareholding

No Data

Shareholder Activity

Name

Shares Held

Chg %

Brandes Investment Partners, L.P.

Star Investors

25.74M

+25.59%

Capital World Investors

21.52M

+1.84%

Permian Investment Partners, LP

18.08M

+11.70%

Black Creek Investment Management, Inc.

12.69M

+12.79%

Millennium Management LLC

8.57M

-8.38%

Armistice Capital LLC

9.28M

-7.55%

Soleus Capital Management, L.P.

7.09M

+7.33%

Janus Henderson Investors

3.05M

Harris Associates L.P.

Star Investors

3.44M

-7.65%

BofA Global Research (US)

1.98M

-50.91%

Risk Assessment

Currency: USD Updated: 2025-09-19

The company’s current risk assessment score is 5.09, which is higher than the Pharmaceuticals industry's average of 4.07. The company's beta value is 0.69. This indicates that the stock tends to underperform the index during upward trending markets but experiences smaller declines during downward trending markets.